Real-life LDL-C treatment goals achievement in patients with
heterozygous familial hypercholesterolemia in the Czech
Republic and Slovakia: Results of the PLANET registry

J 2018

Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry

VRABLIK, Michal, Katarina RASLOVA, Branislav VOHNOUT, Vladimir BLAHA, Martin SATNY et. al.

Základní údaje

Originální název

Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry

Autoři

VRABLIK, Michal (203 Česká republika), Katarina RASLOVA (703 Slovensko), Branislav VOHNOUT (703 Slovensko), Vladimir BLAHA (203 Česká republika), Martin SATNY (203 Česká republika), Ondřej KYSELÁK (203 Česká republika), Martina VACLOVA (203 Česká republika), Robin URBANEK (203 Česká republika), Jana MASKOVA (203 Česká republika), Vladimír SOŠKA (203 Česká republika, domácí) a Tomáš FREIBERGER (203 Česká republika, garant, domácí)

Vydání

Atherosclerosis, Clare, ELSEVIER SCI IRELAND LTD, 2018, 0021-9150

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30230 Other clinical medicine subjects

Stát vydavatele

Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 4.255

Kód RIV

RIV/00216224:14110/18:00105337

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.atherosclerosis.2018.08.008

UT WoS

000445908000054

Klíčová slova anglicky

Familial hypercholesterolemia; LDL-C goal attainment; Treatment pattern; LDL-Cholesterol; Statins; Ezetimibe

Štítky

14110114, 14110116, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 12. 3. 2019 16:03, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

Background and aims: Despite the high prevalence of familial hypercholesterolemia (FH) and available effective lipid-lowering therapy, most of the individuals with this disorder remain undiagnosed and undertreated. The aim of the PLANET registry was to assess the real-life attainment of low-density lipoprotein cholesterol (LDL-C) therapeutic target level in patients with heterozygous FH, to characterize prescribed lipid-lowering therapy with assessment of its efficiency according to the attainment of the target LDL-C level, and to characterize cardiovascular events observed in this patient population again in relation to LDL-C target level attainment. Methods: PLANET registry was designed as a non-interventional, retrospective, cross-sectional, multicentre disease registry for adult patients with heterozygous FH in the Czech Republic and Slovakia. Results: Overall, 1755 patients were enrolled at 32 sites specialized in FH treatment. 15.4% of patients attained the target LDL-C value. The proportion of patients with LDL-C goal achievement increased to 17.3% in the subgroup of patients receiving high-intensity statin therapy (54.6% of study population). Out of 55 patients receiving inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9), 61.8% reached the LDL-C treatment goal. Of all cardiovascular events reported, 14.0% occurred in patients attaining the LDL-C goal, while it was 86.0% in the not-at-target group. It was documented (p= 0.004) that the longer is the patient in care at the specialized FH centre, the higher is the probability that he/she will attain the target LDL-C level. Conclusions: Although target LDL-C level attainment remains relatively low, the likelihood of LDL-C goal attainment increases with duration of specialized care.

Citovat

VRABLIK, Michal, Katarina RASLOVA, Branislav VOHNOUT, Vladimir BLAHA, Martin SATNY, Ondřej KYSELÁK, Martina VACLOVA, Robin URBANEK, Jana MASKOVA, Vladimír SOŠKA a Tomáš FREIBERGER. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry. Atherosclerosis. Clare: ELSEVIER SCI IRELAND LTD, 2018, roč. 277, OCT 2018, s. 355-361. ISSN 0021-9150. Dostupné z: https://dx.doi.org/10.1016/j.atherosclerosis.2018.08.008.

@article{1484536,
   author = {Vrablik, Michal and Raslova, Katarina and Vohnout, Branislav and Blaha, Vladimir and Satny, Martin and Kyselák, Ondřej and Vaclova, Martina and Urbanek, Robin and Maskova, Jana and Soška, Vladimír and Freiberger, Tomáš},
   article_location = {Clare},
   article_number = {OCT 2018},
   doi = {http://dx.doi.org/10.1016/j.atherosclerosis.2018.08.008},
   keywords = {Familial hypercholesterolemia; LDL-C goal attainment; Treatment pattern; LDL-Cholesterol; Statins; Ezetimibe},
   language = {eng},
   issn = {0021-9150},
   journal = {Atherosclerosis},
   title = {Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry},
   volume = {277},
   year = {2018}
}

TY  - JOUR
ID  - 1484536
AU  - Vrablik, Michal - Raslova, Katarina - Vohnout, Branislav - Blaha, Vladimir - Satny, Martin - Kyselák, Ondřej - Vaclova, Martina - Urbanek, Robin - Maskova, Jana - Soška, Vladimír - Freiberger, Tomáš
PY  - 2018
TI  - Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry
JF  - Atherosclerosis
VL  - 277
IS  - OCT 2018
SP  - 355-361
EP  - 355-361
PB  - ELSEVIER SCI IRELAND LTD
SN  - 00219150
KW  - Familial hypercholesterolemia
KW  - LDL-C goal attainment
KW  - Treatment pattern
KW  - LDL-Cholesterol
KW  - Statins
KW  - Ezetimibe
N2  - Background and aims: Despite the high prevalence of familial hypercholesterolemia (FH) and available effective lipid-lowering therapy, most of the individuals with this disorder remain undiagnosed and undertreated. The aim of the PLANET registry was to assess the real-life attainment of low-density lipoprotein cholesterol (LDL-C) therapeutic target level in patients with heterozygous FH, to characterize prescribed lipid-lowering therapy with assessment of its efficiency according to the attainment of the target LDL-C level, and to characterize cardiovascular events observed in this patient population again in relation to LDL-C target level attainment. Methods: PLANET registry was designed as a non-interventional, retrospective, cross-sectional, multicentre disease registry for adult patients with heterozygous FH in the Czech Republic and Slovakia. Results: Overall, 1755 patients were enrolled at 32 sites specialized in FH treatment. 15.4% of patients attained the target LDL-C value. The proportion of patients with LDL-C goal achievement increased to 17.3% in the subgroup of patients receiving high-intensity statin therapy (54.6% of study population). Out of 55 patients receiving inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9), 61.8% reached the LDL-C treatment goal. Of all cardiovascular events reported, 14.0% occurred in patients attaining the LDL-C goal, while it was 86.0% in the not-at-target group. It was documented (p= 0.004) that the longer is the patient in care at the specialized FH centre, the higher is the probability that he/she will attain the target LDL-C level. Conclusions: Although target LDL-C level attainment remains relatively low, the likelihood of LDL-C goal attainment increases with duration of specialized care.
ER  -

VRABLIK, Michal, Katarina RASLOVA, Branislav VOHNOUT, Vladimir BLAHA, Martin SATNY, Ondřej KYSELÁK, Martina VACLOVA, Robin URBANEK, Jana MASKOVA, Vladimír SOŠKA a Tomáš FREIBERGER. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry. \textit{Atherosclerosis}. Clare: ELSEVIER SCI IRELAND LTD, 2018, roč.~277, OCT 2018, s.~355-361. ISSN~0021-9150. Dostupné z: https://dx.doi.org/10.1016/j.atherosclerosis.2018.08.008.

Podrobný výpis o publikaci